Abstract

BackgroundAdipose-derived mesenchymal stem cell (ADMSC) therapy can promote recovery from cerebral ischemia; however, more information regarding appropriate sources of ADMSCs is required. This study was aimed at analyzing the immunogenicity of rat ADMSCs by comparing the immunological effects of intraparenchymal administration of allogeneic ADMSCs (allo-ADMSCs) and autologous ADMSCs (auto-ADMSCs) after the acute phase of middle cerebral artery occlusion (MCAO) in rats.MethodsAllo- or auto-ADMSCs from rats (1 × 106 cells) were transplanted into Lewis rats 8 days post MCAO. The immunogenicity of ADMSCs was analyzed using coculture with T lymphocytes. The in vivo immune response induced by rat ADMSCs and the viability, migration, and differentiation of transplanted ADMSCs were detected using immunohistochemistry. Apoptosis within the populations of transplanted cells were detected using a TUNEL assay. Infarct volume was detected by 2,3,5-triphenyltetrazolium chloride staining. Post-treatment neurological function was evaluated using a modified neurological severity score and rotarod test. Data were analyzed using Kruskal–Wallis and Mann–Whitney U tests.ResultsCompared with allo-ADMSCs, auto-ADMSCs showed lower immunogenicity and evoked weaker immunological responses. Allo-ADMSCs evoked significantly stronger protein expression of interleukin-2 and interferon-gamma, as well as the local accumulation of CD4+ T lymphocytes, CD8+ T lymphocytes, and microglial cells. This indicates that auto-ADMSCs may contribute to higher survival rates, longer survival time, wider migratory scope, and fewer apoptotic cells. In addition, a small number of transplanted auto-ADMSCs expressed astrocyte-like and neuron-like markers 28 days after transplantation. We did not observe surviving transplanted allo-ADMSCs at this time point. We also found that auto-ADMSCs induced a greater degree of functional recovery and a greater reduction in infarct volume than allo-ADMSCs 28 days after transplantation.ConclusionsAuto-ADMSCs were more effective than allo-ADMSCs in promoting recovery and reducing the infarct volume of MCAO rats. This could be associated with better viability, migratory ability, and differentiation potential, as well as a lower rate of apoptosis. Confirmation of the superiority of auto-ADMSCs and clarification of the underlying mechanisms will provide a theoretical basis for the improved clinical treatment of cerebral infarction.

Highlights

  • Adipose-derived mesenchymal stem cell (ADMSC) therapy can promote recovery from cerebral ischemia; more information regarding appropriate sources of adipose-derived mesenchymal stem cells (ADMSCs) is required

  • Immunogenicity of ADMSCs in vitro To characterize the in vitro immunogenicity of ADMSCs, we evaluated the levels of IL-2 and interferon gamma (IFN-γ) in mixed T-lymphocyte cultures prepared with either allo- or auto-ADMSCs

  • There were no significant differences in the production of IFN-γ and IL-2 between cultures with auto-ADMSCs and cultures without ADMSCs

Read more

Summary

Introduction

Adipose-derived mesenchymal stem cell (ADMSC) therapy can promote recovery from cerebral ischemia; more information regarding appropriate sources of ADMSCs is required. This study was aimed at analyzing the immunogenicity of rat ADMSCs by comparing the immunological effects of intraparenchymal administration of allogeneic ADMSCs (allo-ADMSCs) and autologous ADMSCs (auto-ADMSCs) after the acute phase of middle cerebral artery occlusion (MCAO) in rats. Methods: Allo- or auto-ADMSCs from rats (1 × 106 cells) were transplanted into Lewis rats 8 days post MCAO. Cerebral infarct or ischemic stroke is widely regarded as a major cause of disability and mortality [1]. Compared with embryonic stems cells and BMSCs, ADMSCs are advantageous because they are abundant, obtainable with minimal invasiveness, and readily culturable to a sufficient number for autologous transplantation without raising ethical concerns. A previous study demonstrated the therapeutic superiority of ADMSCs over BMSCs in an animal model of ischemic stroke, and in improving brain function and reducing infarct size [8]. A direct comparison of the immune responses elicited by and therapeutic effects of autologous (auto-) versus allo-ADMSCs has not been made to date

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call